title: Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation.
abstract: From July 1995 to December 2001, 42 patients with leukemia aged 1-42 years underwent cord blood transplant (CBT) from unrelated, < or = 2 antigen HLA mismatched donors. In all, 26 patients were in < or = 2nd complete remission and 16 in more advanced phase. Conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive policy were uniform for all patients. The cumulative incidence of engraftment was 90% (95% CI: 0.78-0.91). The cumulative incidence of III-IV grade acute- and chronic-GVHD was 9% (95% CI: 0.04-0.24) and 35% (95% CI: 0.21-0.60), respectively. The 4-year cumulative incidence of transplant-related mortality (TRM) and relapse was 28% (95% CI: 0.17-0.47) and 25% (95% CI: 0.14-0.45), respectively. The 4-year overall survival (OS), leukemia-free survival (LFS) and event-free survival (EFS) were 45% (95% CI: 0.27-0.63), 47% (95% CI: 0.30-0.64) and 46% (95% CI: 0.30-0.62), respectively. In multivariate analysis, the most important factor affecting outcomes was the CFU-GM dose, associated with CMV serology (P=0.003 and 0.04, respectively) in influencing OS and with patient sex (P=0.008 and 0.03, respectively) in influencing LFS. Finally, CFU-GM dose was the only factor that affected EFS significantly (P=0.02). In conclusion, the infused cell dose expressed as in vitro progenitor cell growth is highly predictive of outcomes after an unrelated CBT and should be considered the main parameter in selecting cord blood units for transplant.
authors.affiliation: Department of Cell Biotechnology and Hematology, University 'La Sapienza', Rome.
authors.forename: A P
authors.initials: AP
authors.lastname: Iori
authors.forename: R
authors.initials: R
authors.lastname: Cerretti
authors.forename: L
authors.initials: L
authors.lastname: De Felice
authors.forename: M
authors.initials: M
authors.lastname: Screnci
authors.forename: A
authors.initials: A
authors.lastname: Mengarelli
authors.forename: A
authors.initials: A
authors.lastname: Romano
authors.forename: M
authors.initials: M
authors.lastname: Caniglia
authors.forename: L
authors.initials: L
authors.lastname: Cerilli
authors.forename: G
authors.initials: G
authors.lastname: Gentile
authors.forename: M L
authors.initials: ML
authors.lastname: Moleti
authors.forename: F
authors.initials: F
authors.lastname: Giona
authors.forename: F
authors.initials: F
authors.lastname: Agostini
authors.forename: I
authors.initials: I
authors.lastname: Pasqua
authors.forename: M P
authors.initials: MP
authors.lastname: Perrone
authors.forename: M R
authors.initials: MR
authors.lastname: Pinto
authors.forename: L
authors.initials: L
authors.lastname: Grapulin
authors.forename: A M
authors.initials: AM
authors.lastname: Testi
authors.forename: P
authors.initials: P
authors.lastname: Martino
authors.forename: G
authors.initials: G
authors.lastname: De Rossi
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: W
authors.initials: W
authors.lastname: Arcese
mesh_terms: D000293:Adolescent; D000328:Adult; D002452:Cell Count; D002648:Child; D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data*; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008137:Longitudinal Studies; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D014019:Tissue Donors; D016896:Treatment Outcome